Novo Nordisk (UK) Today
| 0QIU Stock | 742.30 14.79 2.03% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Novo Nordisk is selling for under 742.30 as of the 25th of November 2024; that is 2.03 percent increase since the beginning of the trading day. The stock's lowest day price was 726.75. Novo Nordisk has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Novo Nordisk AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Commercial & Professional Services | Classification Industrials |
Novo Nordisk is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 2.41 B outstanding shares. More on Novo Nordisk AS
Moving together with Novo Stock
Moving against Novo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Novo Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novo Nordisk's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novo Nordisk or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Novo Nordisk's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novo Nordisk's managers, analysts, and investors.
Environment Score | Governance Score | Social Score |
Novo Nordisk AS (0QIU) is traded on London Exchange in UK and employs 59,337 people. Novo Nordisk is listed under Environmental & Facilities Services category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 19.9 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novo Nordisk's market, we take the total number of its shares issued and multiply it by Novo Nordisk's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novo Nordisk AS operates under Commercial Services & Supplies sector and is part of Industrials industry. The entity has 2.41 B outstanding shares.
Novo Nordisk generates positive cash flow from operations, but has no cash available
Check Novo Nordisk Probability Of Bankruptcy
Ownership AllocationNovo Nordisk AS maintains a total of 2.41 Billion outstanding shares. 30% of Novo Nordisk outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novo Ownership Details
Novo Nordisk AS Risk Profiles
Although Novo Nordisk's alpha and beta are two of the key measurements used to evaluate Novo Nordisk's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.43 | |||
| Standard Deviation | 1.88 | |||
| Variance | 3.53 | |||
| Risk Adjusted Performance | (0.12) |
Novo Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novo Nordisk without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Novo Nordisk Corporate Management
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marcus Schindler | Head EVP | Profile | |
| Monique Carter | Head VP | Profile | |
| Maziar Doustdar | Head VP | Profile | |
| Henrik Wulff | Head VP | Profile | |
| Ludovic Helfgott | Head VP | Profile |
Additional Tools for Novo Stock Analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.